April 24th 2024
During a Case-Based Roundtable® event, Evan J. Lipson, MD, discussed with participants how their experience with immunotherapy toxicities has changed over time in the first article of a 2-part series.
December 19th 2023
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Pembrolizumab Extends Survival Versus Chemotherapy in Metastatic Melanoma
November 19th 2014Pembrolizumab (Keytruda) significantly improved progression-free survival (PFS) by over 43% compared with chemotherapy as a treatment for patients with metastatic melanoma who were refractory to ipilimumab (Yervoy).
Read More
Frontline Nivolumab Improves OS, PFS Versus Dacarbazine in Advanced Melanoma
November 19th 2014Frontline treatment with nivolumab (Opdivo) significantly extended overall survival (OS) and progression-free survival (PFS) when compared with dacarbazine in patients with untreated BRAF wild-type advanced melanoma.
Read More
Current and Potential Breakthroughs in Melanoma Treatment
October 15th 2014Nanotechnology is unlikely to enter the arena of melanoma therapy, overshadowed as it is by the promising developments in combination treatment with immune checkpoint inhibitors, tumor-infiltrating lymphocyte therapies, and other immunotherapies.
Read More
Nivolumab Effective as Second-Line Treatment for Advanced Melanoma
September 29th 2014Treatment with nivolumab (Opdivo) demonstrated superior objective response rates (ORR) and longer durations of response compared with chemotherapy in a phase III trial of patients with previously treated advanced metastatic melanoma
Read More
Resistance in Melanoma May Be Addressed With MAPK Inhibitors and Immunotherapies
September 18th 2014Of the many signaling cascades being targeted for therapeutic intervention in cancer, one of the most important and best understood is the MAPK pathway, particularly the RAS/RAF/MEK/ERK cascade.
Read More
Challenges Apparent With Current Targeted Therapies for BRAF Metastatic Melanoma
September 18th 2014Several advances in the treatment of metastatic melanoma have occurred in the last 5 years, one of which has been the approval by the FDA of targeted treatments for patients with melanomas harboring a BRAF mutation.
Read More
Approvals Open Up New Potential Checkpoint Strategies in Metastatic Melanoma
September 13th 2014Since the FDA approval of ipilimumab, there has been considerable interest in the potential for other immune system checkpoints, such as PD-L1 and its receptor, PD-1, to serve as therapeutic targets in metastatic melanoma.
Read More
Bristol-Myers Squibb Files Suit Over Merck's Pembrolizumab
September 11th 2014Bristol-Myers Squibb has filed a lawsuit over Merck’s newly approved immunotherapy drug pembrolizumab, contending that the much-heralded PD-1 inhibitor will infringe upon patents that Bristol-Myers holds on the groundbreaking technology.
Read More
T-VEC in Combination with Ipilmumab for Melanoma Treatment
August 30th 2014Igor Puzanov, MD, medical oncologist, Vanderbilt-Ingram Cancer Center, discusses the rationale behind a phase Ib study to evaluate the efficacy and safety of T-VEC and ipilimumab in previously untreated, unresected stage IIIB-IV melanoma
Watch